fludarabine + cyclophosphamide + TAA05 cell injection

This combination therapy consists of two chemotherapeutic agents—fludarabine and cyclophosphamide—used as lymphodepleting preconditioning agents, followed by infusion of TAA05 cell injection. Fludarabine is a purine analog antimetabolite that inhibits DNA synthesis and is commonly used in hematologic malignancies[6][8]. Cyclophosphamide is an alkylating agent that crosslinks DNA to prevent cancer cell replication. The third component, TAA05 cell injection, is an investigational chimeric antigen receptor (CAR) T-cell therapy targeting Fms-like tyrosine kinase 3 (FLT3), a surface marker frequently expressed in acute myeloid leukemia (AML)[5][4][3]. In this approach, autologous or allogeneic T cells are genetically engineered to express a CAR specific for FLT3; these modified cells are then expanded and infused into the patient after lymphodepletion with fludarabine and cyclophosphamide. The primary indication under investigation for this regimen is relapsed or refractory FLT3-positive acute myeloid leukemia[5][4][1]. The developer of the TAA05 product is PersonGen Biotherapeutics.

Other names

FLT3 CAR-T cell therapyFLT-3 CAR-T cell therapyFLT 3 CAR-T cell therapyanti-FLT3 CAR-T cell (for TAA05 component)